Haemonetics (NYSE:HAE) and KORU Medical Systems (NASDAQ:KRMD) Financial Contrast

Haemonetics (NYSE:HAE – Get Rating) and KORU Medical Systems (NASDAQ:KRMD – Get Rating) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, institutional ownership, dividends and analyst recommendations.

Insider and Institutional Ownership

36.1% of KORU Medical Systems shares are held by institutional investors. 1.7% of Haemonetics shares are held by company insiders. Comparatively, 34.0% of KORU Medical Systems shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Haemonetics and KORU Medical Systems’ gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Haemonetics	$993.20 million	3.93	$43.38 million	$1.85	41.84
KORU Medical Systems	$27.90 million	6.15	-$8.66 million	($0.20)	-18.85

Haemonetics has higher revenue and earnings than KORU Medical Systems. KORU Medical Systems is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings for Haemonetics and KORU Medical Systems, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Haemonetics	0	2	4	0	2.67
KORU Medical Systems	0	0	3	0	3.00

Haemonetics currently has a consensus price target of $101.00, indicating a potential upside of 30.47%. KORU Medical Systems has a consensus price target of $4.17, indicating a potential upside of 10.52%. Given Haemonetics’ higher probable upside, research analysts plainly believe Haemonetics is more favorable than KORU Medical Systems.

Profitability

This table compares Haemonetics and KORU Medical Systems’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Haemonetics	8.48%	19.84%	8.08%
KORU Medical Systems	-31.05%	-24.21%	-18.59%

Volatility and Risk

Haemonetics has a beta of 0.43, meaning that its share price is 57% less volatile than the S&P 500. Comparatively, KORU Medical Systems has a beta of 0.42, meaning that its share price is 58% less volatile than the S&P 500.

Summary

Haemonetics beats KORU Medical Systems on 10 of the 14 factors compared between the two stocks.

About Haemonetics

(Get Rating)

Haemonetics Corp. is a global healthcare company, which engages in the development and distribution of hematology products and solutions. It operates through the following segments: Plasma, Blood Center, Hospital, and Corporate. The Plasma segment offers automated plasma collection and donor management software systems. The Blood Center segment provides solutions for donor collection centers’ ability to acquire blood, filter blood, and separate blood components. The Hospital segment includes hemostasis management, cell salvage, and transfusion management services that help decision makers in hospitals optimize blood acquisition, storage, and usage in critical settings. The company was founded by Allen Latham, Jr. in 1971 and is headquartered in Boston, MA.

About KORU Medical Systems

(Get Rating)

KORU Medical Systems, Inc. engages in the design, manufacture, and market of proprietary medical devices. Its product portfolio includes FREEDOM60, FreedomEdge syringe drivers, Precision Flow Rate Tubing, and HIgH-Flo Subcutaneous Safety Needle Sets. The company was founded by Andrew I. Sealfon and Adrian W. Zorgniotti on March 24, 1980 and is headquartered in Mahwah, NJ.